Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Hashimoto, Yuuri, Koyama, Kumiko, Kamai, Yasuki, Hirotani, Kenji, Ogitani, Yusuke, Zembutsu, Akiko, Abe, Manabu, Kaneda, Yuki, Maeda, Naoyuki, Shiose, Yoshinobu, Iguchi, Takuma, Ishizaka, Tomomichi, Karibe, Tsuyoshi, Hayakawa, Ichiro, Morita, Koji, Nakada, Takashi, Nomura, Taisei, Wakita, Kenichi, Kagari, Takashi, Abe, Yuki, Murakami, Masato, Ueno, Suguru, Agatsuma, Toshinori · 2019 · Clinical Cancer Research

Abstract

Purpose: HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available. Here, we produced U3-1402, an anti-HER3 antibody–drug conjugate with a topoisomerase I inhibitor exatecan derivative (DXd), and systematically investigated its targeted drug delivery potential and antitumor activity in preclinical models. Experimental Design: In vitro pharmacologic activities and the mechanisms of action of U3-1402 were assessed in several human cancer cell lines. Antitumor activity of U3-1402 was evaluated in xenograft mouse models, including patient-derived xenograft (PDX) models. Safety assessments were also conducted in rats and monkeys. Results: U3-1402 showed HER3-specific binding followed by highly efficient cancer cell internalization. Subsequently, U3-1402 was translocated to the lysosome and released its payload DXd. While U3-1402 was able to inhibit HER3-activated signaling similar to its naked antibody patritumab, the cytotoxic activity of U3-1402 in HER3-expressing cells was predominantly mediated by released DXd through DNA damage and apoptosis induction. In xenograft mouse models, U3-1402 exhibited dose-dependent and HER3-dependent antitumor activity. Furthermore, U3-1402 exerted potent antitumor activity against PDX tumors with HER3 expression. Acceptable toxicity was noted in both rats and monkeys. Conclusions: U3-1402 demonstrated promising antitumor activity against HER3-expressing tumors with tolerable safety profiles. The activity of U3-1402 was driven by HER3-mediated payload delivery via high internalization into tumor cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1745

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 178

Metadata

Authors
Hashimoto, Y., Koyama, K., Kamai, Y., Hirotani, K., Ogitani, Y., Zembutsu, A., Abe, M., Kaneda, Y., Maeda, N., Shiose, Y., Iguchi, T., Ishizaka, T., Karibe, T., Hayakawa, I., Morita, K., Nakada, T., Nomura, T., Wakita, K., Kagari, T., Abe, Y., Murakami, M., Ueno, S., & Agatsuma, T.
Venue
Clinical Cancer Research
Published
2019-12-01
Volume
25
Issue
23
Pages
7151-7161
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2970626931
Cited by
178
References
6
FWCI
5.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1745
The paper
Hashimoto, Y., Koyama, K., Kamai, Y., Hirotani, K., Ogitani, Y., Zembutsu, A., Abe, M., Kaneda, Y., Maeda, N., Shiose, Y., Iguchi, T., Ishizaka, T., Karibe, T., Hayakawa, I., Morita, K., Nakada, T., Nomura, T., Wakita, K., Kagari, T., . . . Agatsuma, T. (2019). A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1745

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.